Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By Region and Competition, 2020-2030F

Description

The Global Losartan Market was valued at USD 728.50 Million in 2024 and is projected to reach USD 898.16 Million by 2030, growing at a CAGR of 3.75%. Losartan, an angiotensin II receptor blocker (ARB), is extensively prescribed for managing hypertension, heart failure, and diabetic nephropathy. Its clinical efficacy, affordability, and safety profile have contributed to its broad utilization across diverse global healthcare systems. The growing burden of lifestyle-related illnesses such as obesity, hypertension, and type 2 diabetes-especially among aging populations-has significantly bolstered demand for antihypertensive medications like losartan. Additionally, increasing public awareness around chronic disease prevention, the growth of the generic pharmaceutical sector, and the promotion of accessible treatments are further propelling market expansion. However, challenges such as product recalls linked to contamination and sustained pricing pressures due to intense generic competition have tempered profitability for some manufacturers. Despite these constraints, losartan remains a mainstay in cardiovascular therapy across both mature and emerging markets.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 728.50 Million
Market Size 2030	USD 898.16 Million
CAGR 2025-2030	3.75%
Fastest Growing Segment	Contract Manufacturing Organizations
Largest Market	North America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, with annual sales surpassing USD 4 trillion, continues to drive the growth of the losartan market. Key segments such as pharmaceuticals and biotechnology account for over USD 850 billion, while diagnostics and medical technology contribute more than USD 400 billion. As healthcare systems worldwide scale up to meet the rising prevalence of chronic conditions, there is heightened focus on early intervention and long-term management strategies for cardiovascular and renal diseases. This has elevated the demand for effective antihypertensive agents, with losartan positioned as a first-line option due to its efficacy in managing blood pressure and reducing the risk of stroke and kidney damage in diabetic patients. Increased healthcare spending, particularly in developing countries, along with broader access to generics, is further accelerating market growth.

Key Market Challenges

Disruption in Supply Chain

Supply chain disruptions pose a persistent challenge to the global losartan market, impacting the availability and timely distribution of both active pharmaceutical ingredients (APIs) and finished formulations. The production of losartan heavily depends on stable API sourcing, predominantly from manufacturing hubs in India and China. Any disruption caused by regulatory non-compliance, factory shutdowns, environmental restrictions, or geopolitical tensions can lead to delays and shortages. In addition, reliance on limited global suppliers creates bottlenecks, especially during periods of heightened demand. These interruptions not only affect drug availability but can also lead to price fluctuations, undermining supply chain resilience and complicating inventory management for manufacturers and healthcare providers alike.

Key Market Trends

Increasing Research into Combination Therapies

A growing trend shaping the losartan market is the increasing focus on fixed-dose combination therapies for the treatment of hypertension and related cardiovascular disorders. With the complexity of disease management rising, pharmaceutical companies are exploring synergistic formulations that combine losartan with complementary antihypertensive agents such as hydrochlorothiazide or amlodipine. These combination therapies aim to improve therapeutic outcomes, simplify dosing regimens, and boost patient adherence. Inspired by successful models in oncology and other chronic disease areas, this trend is supported by clinical data demonstrating enhanced efficacy and patient satisfaction. Fixed-dose combinations also offer pharmaceutical companies a pathway to differentiate their products in a competitive generic market, helping to extend product lifecycles and align with evolving clinical guidelines that prioritize combination treatment strategies.

Key Market Players

Merck & Co. Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Novartis International AG
Dr. Reddy's Laboratories Ltd.
Sun Pharmaceuticals Industries Ltd.
Aurobindo Pharma Ltd.
Torrent Pharmaceutical Ltd.
Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

Contract Manufacturing Organizations
In-House

Losartan Market, By Application:

Hypertension
Stroke
Diabetic Nephropathy
Others

Losartan Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Losartan Market

5. Global Losartan Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
- 5.2.2. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Losartan Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Source
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Losartan Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Source
    - 6.3.1.2.2. By Application
- 6.3.2. Mexico Losartan Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Source
    - 6.3.2.2.2. By Application
- 6.3.3. Canada Losartan Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Source
    - 6.3.3.2.2. By Application

7. Europe Losartan Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Source
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Losartan Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Source
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Losartan Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Source
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Losartan Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Source
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Losartan Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Source
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Losartan Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Source
    - 7.3.5.2.2. By Application

8. Asia Pacific Losartan Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Source
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Losartan Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Source
    - 8.3.1.2.2. By Application
- 8.3.2. India Losartan Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Source
    - 8.3.2.2.2. By Application
- 8.3.3. South Korea Losartan Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Source
    - 8.3.3.2.2. By Application
- 8.3.4. Japan Losartan Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Source
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Losartan Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Source
    - 8.3.5.2.2. By Application

9. South America Losartan Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Source
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Losartan Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Source
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Losartan Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Source
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Losartan Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Source
    - 9.3.3.2.2. By Application

10. Middle East and Africa Losartan Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Source
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Losartan Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Source
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Losartan Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Source
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Losartan Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Source
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Losartan Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Merck & Co. Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Pfizer Inc.
16.3. Teva Pharmaceutical Industries Ltd.
16.4. Sanofi S.A.
16.5. Novartis International AG
16.6. Dr. Reddy's Laboratories Ltd.
16.7. Sun Pharmaceuticals Industries Ltd.
16.8. Aurobindo Pharma Ltd.
16.9. Torrent Pharmaceutical Ltd.
16.10. Lupin Ltd.